avb3 integrin has been reported as a promising therapeutic target for angiogenesis. In the present study, we tested the antiangiogenic activity of 3-[3-(6-guanidino-1-oxoisoindolin-2-yl) propanamido]-3-(pyridin-3-yl) propanoic acid dihydrochloride (GOPPP), a novel non-peptide avb3 antagonist. Both @entity1 umbilical vein endothelial cells (HUVECs) and a @entity19 model of @entity26 -induced @entity989 (OIR) were investigated separately. HUVEC adhesion, proliferation, migration, @entity8837 and Akt phosphorylation were assessed. C57BL/6 @entity19 were used for the studies in the OIR model. After exposure to 75% @entity26 from @entity227 ( @entity227 ) 7 to PD12, the @entity19 were returned to room air, and GOPPP was intravitreally administered on PD12. @entity2479 was evaluated on PD17. @entity519 -inducible factor-1a ( @entity1965 ) and @entity1611 ( @entity1611 ) protein levels and @entity8837 phosphorylation were determined by Western blot analysis of retina proteins. GOPPP significantly inhibited the pro-angiogenic effects of vitronectin on HUVECs, including adhesion, proliferation, and migration, and inhibited @entity8837 and Akt phosphorylation. @entity2479 in the OIR model was significantly suppressed by intravitreal administration of 50  ng GOPPP. The pro-angiogenic factors @entity1965 and @entity1611 induced by @entity519 were significantly inhibited by GOPPP in OIR @entity19 . GOPPP administration also inhibited @entity8837 phosphorylation in the OIR model. These results indicate that GOPPP, a novel avb3 integrin antagonist, may have potential for the treatment of pathological retinal angiogenesis.

Therapeutic efficacy of a novel non-peptide avb3 integrin antagonist for pathological retinal angiogenesis in XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity227 :: ('MESH:D014786', 'Disease') :: ['postnatal day', 'PD'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['Retinal neovascularization'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity519 :: ('MESH:D000860', 'Disease') :: ['Hypoxia', 'hypoxia'] @entity1965 :: ('15251(Tax:10090)', 'Gene') :: ['HIF-1a'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy'] @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['vascular endothelial growth factor', 'VEGF'] @entity8837 :: ('26417;26413', 'Gene') :: ['ERK1/2']
@entity19 :: (10090,Species) :: ['mice']
